FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $83,738 | -16.5% | 17,592 | 0.0% | 0.00% | – |
| Q1 2023 | $100,274 | -43.5% | 17,592 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $177,503 | -54.9% | 17,592 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $394,000 | -9.6% | 17,592 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $436,000 | -36.1% | 17,592 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $682,000 | -33.7% | 17,592 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $1,029,000 | -1.3% | 17,592 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $1,043,000 | -31.7% | 17,592 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $1,527,000 | +5.3% | 17,592 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $1,450,000 | -9.4% | 17,592 | 0.0% | 0.01% | -16.7% |
| Q4 2020 | $1,600,000 | +99.3% | 17,592 | -12.4% | 0.01% | +50.0% |
| Q3 2020 | $803,000 | +16.5% | 20,092 | 0.0% | 0.00% | +33.3% |
| Q2 2020 | $689,000 | +54.5% | 20,092 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $446,000 | +13.5% | 20,092 | 0.0% | 0.00% | +50.0% |
| Q4 2019 | $393,000 | – | 20,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |